A potent EGFR tyrosine kinase inhibitor
Tarceva is different from conventional chemotherapies and has been shown to potently inhibit tyrosine kinase phosphorylation of EGFR. Learn more about cancer cell proliferation, EGFR, dysregulation of EGFR and Tarceva’s mechanism of inhibition.
Approval and labeling information
Tarceva is approved in most European countries. Download the labeling information in your own language to print or save to your computer.
Tarceva.com
This site is only intended for use by healthcare professionals outside of the US. If you are a US resident, please visit www.tarceva.com.
